Prognostic Value of Synaptophysin and Chromogranin A Expression in Patients Receiving Palliative Chemotherapy for Advanced Non-Small-Cell Lung Cancer | Zendy

Dariusz M. Kowalski | Zendy; Maciej Krzakowski | Zendy; Piotr Jaśkiewicz | Zendy; Włodzimierz Olszewski | Zendy; Anna Janowicz-Żebrowska | Zendy; Kamila WojasKrawczyk | Zendy; Paweł Krawczyk | Zendy

Open Access

Prognostic Value of Synaptophysin and Chromogranin A Expression in Patients Receiving Palliative Chemotherapy for Advanced Non-Small-Cell Lung Cancer

Author(s) -

Dariusz M. Kowalski,

Maciej Krzakowski,

Piotr Jaśkiewicz,

Włodzimierz Olszewski,

Anna Janowicz-Żebrowska,

Kamila WojasKrawczyk,

Paweł Krawczyk

Publication year - 2012

Publication title -

respiration

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.264

H-Index - 81

eISSN - 1423-0356

pISSN - 0025-7931

DOI - 10.1159/000337090

Subject(s) - synaptophysin , chromogranin a , medicine , lung cancer , chemotherapy , oncology , neuroendocrine tumors , gastroenterology , immunohistochemistry , urology

Chemotherapy is the principal treatment method for patients with advanced non-small-cell lung cancer (NSCLC). Treatment with platinum-based and novel chemotherapeutic regimens, compared to monotherapy, slightly increases the response rates to 20-40%. The predictive and prognostic values of molecular factors are highly variable; however, data on clinical-demographic factors are still burdened by significant limitations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research